Clinical Report: Evaluating Vancomycin Dosage in Critically Ill Patients

Background

Vancomycin is a critical antibiotic used to treat infections in critically ill patients, particularly those with renal impairment. Accurate dosing is essential to balance efficacy and minimize nephrotoxicity, especially in patients undergoing renal replacement therapy. Recent guidelines, such as the ASHP/IDSA/PIDS/SIDP vancomycin therapeutic monitoring guideline, emphasize the importance of maintaining daily vancomycin exposure within 400–600 mg·h/L to minimize nephrotoxicity and maximize efficacy.

Data Highlights

No numerical or trial data provided in the source material.

Key Findings

• The toxicity threshold for vancomycin dosing simulations was set at AUC0−24 h ≥ 700 mg·h/L, which contradicts the guideline recommendation of maintaining AUC below 600 mg·h/L.
• External validation showed a median prediction error of 81.9% in a distinct TDM dataset, indicating systematic overprediction of vancomycin concentrations.
• Residual urine output was not included as a stratification variable in the nomogram, despite its recognized impact on vancomycin clearance.
• 46.7% of patients in the TDM dataset had urine output ≥ 500 mL/24 h, compared to 21.5% in the development dataset, suggesting a potential bias in model performance.
• The authors are urged to revise the toxicity threshold to align with the guideline recommendation of 600 mg·h/L and acknowledge limitations in external validation reporting.

Clinical Implications

Clinicians should be cautious when applying the proposed vancomycin dosing nomograms, particularly in patients with residual urine output. Therapeutic drug monitoring is essential to ensure appropriate dosing and minimize the risk of nephrotoxicity.

Conclusion

The findings indicate the need for careful interpretation of vancomycin dosing nomograms in critically ill patients. Adjustments to toxicity thresholds and thorough reporting of validation data are necessary for safe clinical application.

Related Resources & Content

1. Ulldemolins et al., Critical Care, 2025 -- Evaluating Vancomycin Dosage in Critically Ill Patients Undergoing Renal Replacement Therapy
2. ASHP/PIDS/SIDP/IDSA Revised Consensus Guideline and Review for Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant Staphylococcus aureus Infections
3. Critical Care — Optimal Vancomycin Trough Levels: 10–15 mg/L May Suffice for Pharmacodynamic Goals, but Elevated Levels Could Lead to Nephrotoxicity – A Counter Perspective
4. Critical Care (Springer) — Reconsidering vancomycin trough targets in critically-ill patients
5. Critical Care (Springer) — Vancomycin trough levels: it’s not one-size-fits-all
6. Open Forum Infectious Diseases — Comparative Analysis of Acute Kidney Injury Incidence Between Area Under the Concentration–Time Curve and Trough-Based Vancomycin Dosing in Obese Patients
7. Optimal Vancomycin Trough Levels: 10–15 mg/L May Suffice for Pharmacodynamic Goals, but Elevated Levels Could Lead to Nephrotoxicity – A Counter Perspective
8. Reconsidering vancomycin trough targets in critically-ill patients
9. Vancomycin trough levels: it’s not one-size-fits-all
10. ASHP/PIDS/SIDP/IDSA Revised Consensus Guideline and Review for Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant Staphylococcus aureus Infections
11. Optimizing Vancomycin Dosing in Continuous Renal Replacement Therapy: A Systematic Review of Population Pharmacokinetic Studies in Adult Critically Ill Patients